Sun Pharmaceutical, one of the leading players in the Indian Pharmaceutical industry with global operations, has received tentative approval from the United States Food and Drug Administration (USFDA), to market Oxaliplatin injection in the strengths of 50 mg and 100 mg.

Oxaliplatin is a chemotherapy drug that is given as a treatment for some types of cancer. It is most commonly used to treat cancer of the large bowel.

Earlier this month, the company has secured tentative approval from the USFDA, to market Alfuzosin Hydrochloride tablet in the strength of 10 mg.

Alfuzosin is an alpha 1 blocker for the treatment of the signs and symptoms of BPH. Shares of the company declined Rs 109, or 8.24%, to close at Rs 1210.

The total volume of shares traded was 295113 at the BSE (Friday).